AKUMSAkums Drugs and Pharmaceuticals Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.9 this quarter.
Momentum from moving averages, Supertrend and RSI.
2 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
2 found · risk elevated
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹1342 Cr | ₹115 Cr | 11.29% | 8.53% | ₹7.37 | 7.0x |
| Q1 FY2027 | ₹1167 Cr | ₹101 Cr | 11.45% | 8.66% | ₹6.53 | 6.6x |
| Q4 FY2026 | ₹1158 Cr | ₹81 Cr | 9.64% | 7.02% | ₹5.53 | 6.1x |
| Q3 FY2026 | ₹1160 Cr | ₹68 Cr | 9.25% | 5.84% | ₹4.33 | 5.2x |
| Q2 FY2026 | ₹1018 Cr | ₹43 Cr | 5.56% | 4.20% | ₹2.66 | 3.8x |
| Q1 FY2026 | ₹1024 Cr | ₹65 Cr | 8.99% | 6.32% | ₹4.15 | 5.1x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules for therapeutic areas, such as gynaecology, cardiology, orthopaedics, pediatrics, and dermatology, as well as anti-infectives, pain management and gastroenterology. In addition, the company operates as pharmaceutical contract development and manufacturing company. The company was incorporated in 2004 and is based in Delhi, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.